ReviewBioMed research international2015
Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations.
Review in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Rapid assessment of direct oral anticoagulants in acute stroke-An educational systematic review.European stroke journal · 2025Pooled it
- Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting in Patients With or Without Heparin Bridging.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2018Trial
- Inside the 'Black Box' of Pharmaceuticalisation: NICE, the Permissive Principle and the Case of Anticoagulants.Sociology of health & illness · 2026Article
- Pilot study on the probability of drug-drug interactions among direct oral anticoagulants (DOACs) and antiseizure medications (ASMs): a clinical perspective.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Stability of Direct Oral Anticoagulants Concentrations in Blood Samples for Accessibility Expansion of Chromogenic Assays.Medicina (Kaunas, Lithuania) · 2023Article
- Systemic metastasis-targeted nanotherapeutic reinforces tumor surgical resection and chemotherapy.Nature communications · 2021Article
- Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants.Journal of thrombosis and haemostasis : JTH · 2019Observational
- Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.Journal of the American Heart Association · 2018Observational
- Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry.Internal and emergency medicine · 2018Observational
- Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.Thrombosis and haemostasis · 2018Article
- Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation.Journal of thrombosis and thrombolysis · 2018Article
- Comparison of different laboratory tests in the evaluation of hemorrhagic risk of patients using rivaroxaban in the critical care setting: diagnostic accuracy study.Thrombosis journal · 2017Article
- Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: Views from a workshop at the European Medicines Agency (EMA).European heart journal. Cardiovascular pharmacotherapy · 2017Review
- Reversal agents of non-vitamin K dependent anticoagulants: a rapid review of the changing horizon.Archives of medical science : AMS · 2016Article
- Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives.Drug safety · 2016Review
- Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date.Drug, healthcare and patient safety · 2016Review
- Monitoring anticoagulant therapy with new oral agents.World journal of methodology · 2015Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-VKA oral anticoagulants (NOACs) have now widely reached the lucrative market of anticoagulation. While the marketing authorization holders claimed that no routine monitoring is required and that these compounds can be given at fixed doses, several evidences arisen from the literature tend to demonstrate the opposite. New data suggests that an assessment of the response at the individual level could improve the benefit-risk ratio of at least dabigatran. Information regarding the association of rivaroxaban and apixaban exposure and the bleeding risk is available in the drug approval package on the FDA website. These reviews suggest that accumulation of these compounds increases the risk of experiencing a bleeding complication. Therefore, in certain patient populations such as patients with acute or chronic renal impairment or with multiple drug interactions, measurement of drug exposure may be useful to ensure an optimal treatment response. More specific circumstances such as patients experiencing a haemorrhagic or thromboembolic event during the treatment duration, patients who require urgent surgery or an invasive procedure, or patient with a suspected overdose could benefit from such a measurement. This paper aims at providing guidance on how to best estimate the intensity of anticoagulation using laboratory assays in daily practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.